Roche Holding AG - ADR
RHHBY
Get informed when a big investor buys or sells
+ FollowMarket Cap$392.65B
Close$
Earnings Call Q2 2024
July 25, 2024 - AI Summary
Group sales increased by 8% in the first half of the year, excluding COVID impact.
Pharma division saw strong growth in base business with an 8% increase in sales.
Diagnostics division also experienced solid growth with a 9% increase in sales.
Exclusive for Stockcircle Pro members
Sign up
$53.89
11.9% downside
Current Fair Value
11.9% downsideOvervalued by 11.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $392.65 Billion |
|---|---|
| Enterprise Value | $418.86 Billion |
| Dividend Yield | $1.55 (2.51%) |
| Earnings per Share | $2.02 |
| Beta | 0.35 |
| Outstanding Shares | 6,473,904,000 |
Return
| Return on Equity | 66.85% |
|---|---|
| Return on Assets | 22.26% |
| Return on Invested Capital | 42.92% |
Valuation & Multiples
| P/E Ratio | 25.45 |
|---|---|
| PEG | -326.48 |
| Price to Sales | 3.22 |
| Price to Book Ratio | 12.23 |
| Enterprise Value to Revenue | 3.39 |
| Enterprise Value to EBIT | 14.15 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.97 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
$1.58
Average shareholder expectationRevenue Estimate
$38.14 B
Average shareholder expectationNext Earnings Call
Expected Date
February 4, 2027
EPS Estimate
$1.46
Average shareholder expectationRevenue Estimate
$40.09 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 0.06% |
|---|---|
| Total Invested | $81.65M▼ 70.96% |
| Investors Holding | 8▼ 63.00% |
ESG Score
No data
About Roche Holding AG
103,249 employees
CEO: Severin Schwan Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ...